Stock 000423 DONG-E-E-JIAO CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Dong-E-E-Jiao Co.,Ltd.

Equities

000423

CNE0000006Y9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
68.72 CNY +1.64% Intraday chart for Dong-E-E-Jiao Co.,Ltd. -0.15% +39.33%
Apr. 25 Dong-E-E-Jiao Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 12 Dong-E-E-Jiao Forecasts Up to 55% Jump in Q1 Profit MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 22,914 24,928 31,394 26,210 31,761 44,254 - -
Enterprise Value (EV) 1 20,992 23,480 28,164 20,864 25,956 38,236 37,987 37,031
P/E ratio -52 x 553 x 71.7 x 33.6 x 27.6 x 32 x 27.4 x 22.9 x
Yield 0.57% 0.77% 1.33% 2.85% 3.61% 2.84% 2.83% 3.17%
Capitalization / Revenue 7.74 x 7.31 x 8.16 x 6.48 x 6.74 x 7.97 x 6.84 x 5.87 x
EV / Revenue 7.1 x 6.89 x 7.32 x 5.16 x 5.5 x 6.89 x 5.87 x 4.91 x
EV / EBITDA -56.9 x 75 x 38.8 x 19.6 x 17.3 x 23.2 x 19.5 x 16.1 x
EV / FCF -14,416,497 x 33,557,131 x - - - - - -
FCF Yield -0% 0% - - - - - -
Price to Book 2.32 x 2.6 x 3.15 x 2.58 x 2.96 x 4.05 x 3.91 x 3.73 x
Nbr of stocks (in thousands) 647,847 643,977 643,977 643,977 643,977 643,977 - -
Reference price 2 35.37 38.71 48.75 40.70 49.32 68.72 68.72 68.72
Announcement Date 3/26/20 3/19/21 3/25/22 3/24/23 3/21/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,959 3,409 3,849 4,042 4,715 5,550 6,469 7,543
EBITDA 1 -368.7 313 725.6 1,065 1,504 1,648 1,948 2,305
EBIT 1 -513.1 152.1 568.8 914.9 1,360 1,569 1,873 2,237
Operating Margin -17.34% 4.46% 14.78% 22.64% 28.85% 28.27% 28.95% 29.66%
Earnings before Tax (EBT) 1 -505.2 165.7 571.1 912 1,363 1,637 1,914 2,287
Net income 1 -443.9 43.29 440.4 780 1,151 1,388 1,623 1,940
Net margin -15% 1.27% 11.44% 19.3% 24.41% 25% 25.09% 25.72%
EPS 2 -0.6800 0.0700 0.6800 1.210 1.790 2.149 2.512 3.007
Free Cash Flow -1,456 699.7 - - - - - -
FCF margin -49.22% 20.52% - - - - - -
FCF Conversion (EBITDA) - 223.56% - - - - - -
FCF Conversion (Net income) - 1,616.35% - - - - - -
Dividend per Share 2 0.2000 0.3000 0.6500 1.160 1.780 1.951 1.947 2.175
Announcement Date 3/26/20 3/19/21 3/25/22 3/24/23 3/21/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 1,023 890.4 935.4 1,221 995.3 1,069 - 1,261 1,287 1,453 1,346 1,581 1,474 1,588 1,537
EBITDA 1 230.9 159.3 197.6 299.6 - - - - - - 395.2 461 486 516.8 477.4
EBIT 1 201.6 157.1 198.6 268.5 290.8 279 - 312.1 400.3 409.9 378.4 444.3 469.3 493.4 453.9
Operating Margin 19.71% 17.65% 21.23% 21.99% 29.22% 26.1% - 24.75% 31.1% 28.2% 28.11% 28.11% 31.85% 31.07% 29.52%
Earnings before Tax (EBT) 1 200.8 158.2 198.9 265.7 289.1 278.8 - 307.1 407.7 412.2 407.4 478.2 473.5 525.2 483.2
Net income 1 139.2 114.7 193.6 204.6 267.1 230.3 - 252.6 367.2 353.4 344 403.8 394.4 443.4 408
Net margin 13.6% 12.88% 20.69% 16.77% 26.84% 21.55% - 20.03% 28.53% 24.32% 25.55% 25.55% 26.77% 27.93% 26.54%
EPS 2 0.2100 0.1781 0.3000 0.3200 0.4100 0.3577 0.4600 0.4000 0.5700 0.5488 0.5259 0.6174 0.6031 0.6780 0.6238
Dividend per Share 2 - - - - - - - - - - 2.090 - - - 1.377
Announcement Date 3/25/22 4/28/22 8/19/22 10/30/22 3/24/23 4/25/23 8/25/23 10/30/23 3/21/24 4/25/24 - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 1,922 1,448 3,230 5,346 5,805 6,019 6,268 7,223
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -1,456 700 - - - - - -
ROE (net income / shareholders' equity) -4.13% 0.44% 4.47% 7.68% 11.1% 12.7% 14.3% 16.4%
ROA (Net income/ Total Assets) -3.48% 0.38% 3.9% - - 10.1% 11.4% 12.4%
Assets 1 12,764 11,332 11,293 - - 13,808 14,242 15,688
Book Value Per Share 2 15.30 14.90 15.50 15.80 16.60 17.00 17.60 18.40
Cash Flow per Share 2 -1.710 1.220 4.350 3.280 3.030 1.820 2.930 2.760
Capex 1 330 101 24.7 45.5 46.6 140 165 247
Capex / Sales 11.16% 2.97% 0.64% 1.13% 0.99% 2.53% 2.55% 3.28%
Announcement Date 3/26/20 3/19/21 3/25/22 3/24/23 3/21/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Dong-E-E-Jiao Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
68.72 CNY
Average target price
72.43 CNY
Spread / Average Target
+5.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Alternative Medicine

1st Jan change Capi.
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+39.33% 6.11B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-18.38% 4.35B
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-9.17% 3.18B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+3.98% 3.16B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-3.41% 2.51B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+48.74% 1.98B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-4.82% 1.74B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
-1.24% 1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd
-8.96% 1.6B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD Stock Zhejiang Jolly Pharmaceutical Co.,LTD
+39.87% 1.44B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. 000423 Stock
  4. Financials Dong-E-E-Jiao Co.,Ltd.